Hepatocellular Carcinoma as a Complication of Vascular Disease of the Liver After Fontan Procedure
Chiara Mazzarelli, 1,2 Mary D. Cannon, 1 Mark Hudson, 3 Nigel Heaton, 1 Debashis Sarker, 4 Pauline Kane, 5 Alberto Quaglia, 1 and Abid Suddle 1 L iver disease is a recognized complication of the Fontan procedure for cyanotic congenital heart disease. The Fontan procedure is a complex cardio-surgical procedure that diverts systemic venous blood in patients with univentricular hearts directly into the pulmonary arteries, bypassing the right ventricle. (1) The operation has dramatically increased the survival of patients with single ventricle physiology, with 83% surviving to 20 years, without need for cardiac transplantation. However, the increase in life expectancy has led to complications related to chronic complex hemodynamic changes, including liver fibrosis and hepatocellular cancer (HCC).
We report 3 patients who underwent Fontan procedure in childhood and presented with HCC more than 10 years later (Table 1) . Radiologic features were consistent with congestive hepatopathy, with histological confirmation in 2 of 3 patients ( Fig. 1 ). All had HCC beyond Milan criteria for liver transplantation at diagnosis. One patient with tumor within University of California San Francisco criteria received transarterial chemoembolization with successful downstaging and was referred for combined liver-heart transplantation.
Liver disease in Fontan patients (FALD) is strongly associated with the interval from the initial procedure, with a 4.4-times greater risk of FALD for patients 11 to 15 years following surgery, compared with those less than 10 years after Fontan. (3) The fibrogenesis in FALD is a multifactorial process that is related to both chronic congestive venous overflow and systemic hypoxia secondary to left ventricular dysfunction and diffuse pulmonary veno-venous shunts. (1) A recent consensus from the American College of Cardiology has provided general recommendations for the management of FALD. (4) One to three yearly liver function tests and liver ultrasounds have been proposed as a first diagnostic step to identify FALD in adults. However, the diagnosis of liver disease and HCC is challenging, as the clinical presentation is extremely heterogeneous in this patient cohort. Ultrasound and noninvasive assessments of fibrosis are poorly validated in patients with FALD, identifying abnormalities only after liver disease is already established. (4) Moreover, abnormal hepatic blood flow may influence the typical arterial enhancing pattern of HCC on computed tomography imaging, necessitating biopsy to confirm the diagnosis histologically.
Despite yearly ultrasound screenings, all patients in our cohort were diagnosed with HCC beyond the Milan criteria. None of the 3 patients had features of advanced liver disease on diagnostic imaging or liver biopsy. Importantly, cirrhosis is not an absolute requirement for HCC development in patients with FALD or other vascular disorders such as Budd-Chiari syndrome, and additional unrecognized factors beyond the simple hyperplastic hepatocellular response to abnormal liver flow are probably involved in tumorigenesis. (2) The development of HCC after Fontan is a rare event, with the first case series published in 2013. (5) In total, there have been just 18 cases reported in the literature, with only a small number of patients suitable for curable treatment for HCC. The lack of comprehensive screening guidelines for HCC in patients with FALD is likely to have contributed to patients presenting at an advanced stage.
The current practices for assessment of liver disease in patients with FALD are inadequate, and many unanswered questions remain: What are the best methods to detect liver disease? When should screening for HCC commence? We believe surveillance for HCC should start 10 years after Fontan, (1) (2) (3) when significant liver damage is already established. Baseline liver magnetic resonance imaging (MRI) may help to identify high-risk potentially malignant lesions and should be followed with biannual ultrasounds and alpha-fetoprotein tests, regardless of fibrosis stage. MRI should be used for follow-up of patients with high-risk lesions.
An international registry is needed to determine the natural history of liver disease after Fontan. Further studies are warranted to understand whether artiCle iNForMatioN: 
